National Community Pharmacists Association
Postdoctoral Industry Research Fellow, BridgeBio
National Community Pharmacists Association, Boston, Massachusetts, us, 02298
Northeastern University Pharmaceutical Industry Fellowships Program is a two-year experiential program designed to advance lifelong learning and the education and training of Pharm.D. graduates. Critical to the success of the program is our ability to prepare Fellows to meet the ongoing workforce needs in various areas of industry.
Our program provides fellows an opportunity to work with our innovative biopharmaceutical industry partners while collaborating with Northeastern University faculty in the areas of professional and career development, service, scholarship, and teaching.
About BridgeBio:
BridgeBio Pharma Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. BridgeBio exists to bring meaningful medicines to patients as quickly and as safely as possible. We’re passionate about fostering open and transparent relationships with patients and their families by staying connected, listening to their experiences, and applying their insights into our work. We hope that by developing these relationships with patients, families, and patient advocacy organizations early in the development phase of our therapies, we can also craft our clinical trial protocols with the patient experience at the forefront. About Eidos Therapeutics, Inc. a BridgeBio Company
Transthyretin (TTR) amyloidosis (ATTR) is a rare, underdiagnosed, and life-threatening disease with limited treatment options that can damage the heart and/or nervous system. BridgeBio’s mission is to improve the morbidity and mortality of patients with ATTR through the discovery and development of a novel therapeutic through its affiliate, Eidos Therapeutics. In collaboration with Northeastern University, BridgeBio offers a two-year PharmD fellowship in Regulatory Affairs. Application Process:
At this time, we are not accepting PPS interview requests. Individuals who are interested in this position must submit an application to our program to be considered.
Click here
to visit our website and apply today! Requirements:
Doctor of Pharmacy degree from an ACPE accredited institution, eligible for licensure as a pharmacist in the US. Excellent oral and written communication, time management, and leadership skills. Ability to work independently and take initiative on a variety of projects at the industry site and Northeastern.
#J-18808-Ljbffr
BridgeBio Pharma Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015, and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. BridgeBio exists to bring meaningful medicines to patients as quickly and as safely as possible. We’re passionate about fostering open and transparent relationships with patients and their families by staying connected, listening to their experiences, and applying their insights into our work. We hope that by developing these relationships with patients, families, and patient advocacy organizations early in the development phase of our therapies, we can also craft our clinical trial protocols with the patient experience at the forefront. About Eidos Therapeutics, Inc. a BridgeBio Company
Transthyretin (TTR) amyloidosis (ATTR) is a rare, underdiagnosed, and life-threatening disease with limited treatment options that can damage the heart and/or nervous system. BridgeBio’s mission is to improve the morbidity and mortality of patients with ATTR through the discovery and development of a novel therapeutic through its affiliate, Eidos Therapeutics. In collaboration with Northeastern University, BridgeBio offers a two-year PharmD fellowship in Regulatory Affairs. Application Process:
At this time, we are not accepting PPS interview requests. Individuals who are interested in this position must submit an application to our program to be considered.
Click here
to visit our website and apply today! Requirements:
Doctor of Pharmacy degree from an ACPE accredited institution, eligible for licensure as a pharmacist in the US. Excellent oral and written communication, time management, and leadership skills. Ability to work independently and take initiative on a variety of projects at the industry site and Northeastern.
#J-18808-Ljbffr